Capricor Therapeutics (CAPR) Tops Q3 EPS by 5c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.25), $0.05 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $6.19 million versus the consensus estimate of $3.15 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Capricor Therapeutics (CAPR) Reiterates Overweight Rating Ahead of Upcoming PDUFA
• Virax Biolabs signs supply deal with Fosun Diagnostics for SE Asia